In contrast, Mongioì et al. found an increase in TT and LH serum levels of 40 overweight/obese men who consumed VLCKD for at least eight weeks, suggesting that VLCKD is an effective, non-invasive and rapid tool to treat patients with obesity and concomitant metabolic hypogonadism [106]. The gene discussed is PLOD1; the disease is obesity due to melanocortin 4 receptor deficiency.